SCHEMBL989407

SCHEMBL989407

CC(=O)Nc1nc2ccc(C3=C(c4ccccc4)N(Br)CN3C)cc2n1CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 2/20 0.41
EGFR P00533 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TNF P01375 1/20 0.39
ACACB O00763 1/20 0.38
NOD1 Q9Y239 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK14 Q16539 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990046 0.76 KDM4E (0.46) CYP1A2CYP2C9CYP2C19POLBEGFR
SCHEMBL989289 0.65 RORC (0.34) CYP1A2CYP2C9CYP2C19POLBEGFR
SCHEMBL5351831 0.63 CYP1A2 (0.75) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL8423594 0.60 CYP1A2 (1.00) CYP1A2CYP2C9CYP2C19POLBKDM4E
Acetic Acid SCHEMBL27980670 0.60 GAA (0.50) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL2175321 0.60 RAB9A (0.69) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL988471 0.59 CYP2C19 (0.44) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL988473 0.59 CYP2C19 (0.44) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL17819088 0.58 NPSR1 (0.77) CYP1A2CYP2C9CYP2C19POLBKDM4E
SCHEMBL12325962 0.58 KDM4E (0.57) CYP1A2CYP2C9CYP2C19POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed
EP-1720862-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-11-15 EP disclosed
WO-2005080380-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 CYP1A2 3740/4885CYP2C9 3799/4885CYP2C19 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.